Finding Novel Anti-Tuberculosis Compounds

发布时间 :2018-06-14  阅读次数 :520

报告题目Finding Novel Anti-Tuberculosis Compounds

主讲人: Prof. Joo-Won Suh (徐胄源教授)

主讲人简介:

 徐胄源博士1990年到至今为韩国明知大学生命科学情报系教授,2011到至今为韩国21世纪绿色生物食医药素材开发事业项目团团长,曾任韩国微生物与生物技术学会副主席,韩国应用生物化学学会主席,主要研究方向为微生物来源活性天然产物发现及生物合成,主持承担多项韩国政府资助的研究项目,以及多项企业合作研发项目。

报告时间6月19日 (星期二) 下午2:00-3:30

报告地点:上海交大生命学院3-405

联系人: 赵心清 xqzhao@sjtu.edu.cn

 

Abstract:

Tuberculosis (TB) has been known to be an infectious disease caused by Mycobacterium tuberculosis (M. tb) and the MDR (multidrug resistant) and XDR (extensively drug re-sistant) TB incidence currently continue to increase globally. Therefore, the development of new anti-tuberculosis drugs is required for effective treatment of MDR and XDR TB.

In order to address this issue, we screened over 150,000 actinomycetes extracts through in vitro assay using M. tb resistant to existed drugs and isolated two anti-tuberculosis lead compounds as named to Ecumicin and rufomycin. Through DARTS (Drug Affinity Responsive Target Stability) and mutation analysis, we discovered the mode of action that ecumicin and rufomycin, and developed the ClpC1 based screening assay for de-velopment of the ClpC1 inhibitor as anti-tuberculosis lead compounds since M. tb ClpC1 is a druggable target for development of novel anti-tuberculosis lead compounds. This assay has so far been in agreement with payed contraction to GATB (Global Alliance for TB drug development), which is non-profit institute of top-level in TB research support-ed by Bill and Melinda Gates Foundation. Furthermore, we are focusing to produce var-ious cyclic peptides by Split-Intein, which target the ClpC1 specifically. In conclusion, these strategies regarding cyclic peptides targeting M. tb ClpC1 will pave the way for the development of novel anti-tuberculosis lead compounds and eventually save lives from MDR and XDR TB.

 

 

上海交通大学生命科学技术学院 Copyright © 2017 沪交ICP备05029. All Rights Reserved.